BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Melanoma Institute Australia - ECPv6.15.20//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Melanoma Institute Australia
X-ORIGINAL-URL:https://melanoma.org.au
X-WR-CALDESC:Events for Melanoma Institute Australia
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Australia/Sydney
BEGIN:STANDARD
TZOFFSETFROM:+1100
TZOFFSETTO:+1000
TZNAME:AEST
DTSTART:20250405T160000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+1000
TZOFFSETTO:+1100
TZNAME:AEDT
DTSTART:20251004T160000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+1100
TZOFFSETTO:+1000
TZNAME:AEST
DTSTART:20260404T160000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+1000
TZOFFSETTO:+1100
TZNAME:AEDT
DTSTART:20261003T160000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+1100
TZOFFSETTO:+1000
TZNAME:AEST
DTSTART:20270403T160000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+1000
TZOFFSETTO:+1100
TZNAME:AEDT
DTSTART:20271002T160000
END:DAYLIGHT
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Australia/Sydney:20260309T170000
DTEND;TZID=Australia/Sydney:20260309T170000
DTSTAMP:20260416T215625
CREATED:20260203T032013Z
LAST-MODIFIED:20260203T032013Z
UID:10000246-1773075600-1773075600@melanoma.org.au
SUMMARY:Rising Tide Clinical Cancer Research Program
DESCRIPTION:RTFCCR invites academic institutions and not-for-profit organizations to collaborate on innovative\, patient-centered clinical trials. Our mission is to improve cancer patients’ treatment options and quality of life by funding studies focused on detection\, treatment\, and implementation. \nWe support phase I to phase III interventional clinical trials but do not fund basic research\, phase IV trials\, or observational studies. Funding is available to institutions worldwide where effective grant oversight is feasible. \nSubmission Criteria \n\nThe interventional clinical trial can be an early—to—late—stage clinical trial (Phase 1\, 2\, and 3) with a patient partner involvement in the study protocol design.\nOnly applications aimed at detecting and intervening in early cancer (pre-cancerous changes) can also be considered at the pre-clinical validation stage.\nPharmaceutical agents used in the study can be generic (off-patent repurposing)\, registered for this indication\, or under development by an academic institution.\nClinical trials testing immunotherapies should be discussed with RTFCCR before application submission.\nFinal selection will be contingent on scientific review\, strategic portfolio fit\, and availability of funds\n\nKey Dates \nApplication deadlines: 9 March\, 22 June and 23 November 2026 \nSEE FUNDING GUIDELINES PDFSEE WEBSITE
URL:https://melanoma.org.au/event/rising-tide-research-program/
CATEGORIES:Grants,Clinical Trial Cohorts
ATTACH;FMTTYPE=image/jpeg:https://melanoma.org.au/wp-content/uploads/2026/02/RisingTide600-x-338-px.jpg
END:VEVENT
END:VCALENDAR